Cancers, Vol. 11, Pages 1411: Programmed Death –Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC
Cancers, Vol. 11, Pages 1411: Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC
Cancers doi: 10.3390/cancers11101411
Authors:
Julien Ancel
Philippe Birembaut
Maxime Dewolf
Anne Durlach
Béatrice Nawrocki-Raby
Véronique Dalstein
Gonzague Delepine
Silvia Blacher
Gaëtan Deslée
Christine Gilles
Myriam Polette
In non-metastatic non-small-cell lung cancer (NSCLC), outcomes remain poor. Adjuvant chemotherapies provide a limited improvement in disease-free survival. Recent exploratory studies on early-stage NSCLC show that immunotherapy given according to Programmed Death–Ligand 1 expression generates variable results, emphasizing a need to improve tumor characterization. We aimed to conjointly assess NSCLC, the expression of PD–L1, and epithelial–mesenchymal transition, frequently involved in tumor aggressiveness. 188 resected NSCLCs were analyzed. Among 188 patients with curatively resected NSCLC, 127 adenocarcinomas and 61 squamous cell carcinomas were stained for PD–L1 and vimentin expression. Overall survival has been compared regarding PD–L1 and vimentin statuses both separately and conjointly in Tumor Cancer Genome Atlas databases. PD–L1 and vimentin higher expressions were strongly associated (OR = 4.682, p < 0.0001). This co-expression occurred preferentially in tumors with lymph node invasion (p = 0.033). PD&...
Source: Cancers - Category: Cancer & Oncology Authors: Julien Ancel Philippe Birembaut Maxime Dewolf Anne Durlach B éatrice Nawrocki-Raby V éronique Dalstein Gonzague Delepine Silvia Blacher Ga ëtan Deslée Christine Gilles Myriam Polette Tags: Article Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Epithelial Cancer | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Study